Subscribe
shutterstock_685347493_katherine_welles
Katherine Welles / Shutterstock.com
22 September 2020AmericasRory O'Neill

BMS and Dr Reddy’s settle Revlimid suit with generics licence

Bristol Myers Squibb (BMS) and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid (lenalidomide).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
BMS loses UK appeal over blood-thinning drug
9 May 2023   Decision addresses issue of plausibility in invalidation verdict | Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.
Americas
BMS sues over generic of blockbuster leukaemia treatment
4 October 2021   Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.
Americas
BMS boosts cardio portfolio with $13bn buy
6 October 2020   Bristol Myers Squibb has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments.


Editor's picks

‘We created law’: G1/24 and the creation of the ‘diamond standard’
Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025

Editor's picks

Europe
‘We created law’: G1/24 and the creation of the ‘diamond standard’
3 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Americas
BMS loses UK appeal over blood-thinning drug
9 May 2023   Decision addresses issue of plausibility in invalidation verdict | Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.
Americas
BMS sues over generic of blockbuster leukaemia treatment
4 October 2021   Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.
Americas
BMS boosts cardio portfolio with $13bn buy
6 October 2020   Bristol Myers Squibb has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments.

More on this story

Americas
BMS loses UK appeal over blood-thinning drug
9 May 2023   Decision addresses issue of plausibility in invalidation verdict | Case marks first time that Court of Appeal judges held a patent with a single claim to a pharma compound invalid.
Americas
BMS sues over generic of blockbuster leukaemia treatment
4 October 2021   Bristol-Myers Squibb has sued India-based generic maker Alembic over claims that a copycat of the blockbuster leukaemia drug Sprycel, infringes a pair of patents.
Americas
BMS boosts cardio portfolio with $13bn buy
6 October 2020   Bristol Myers Squibb has announced it will acquire biotech firm MyoKardia for $13.1 billion, strengthening its portfolio of heart disease treatments.

More features

‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?